New tumor cases show common gene therapy tool can come with risk

Live updates

1. 57m ago

   FDA Probes Tumor Risk Tied to Novartis Gene Therapy

   Novartis has confirmed nine reported cases of tumors in children treated with its spinal muscular atrophy gene therapy, Zolgensma, prompting an investigation by the Food and Drug Administration. Seven of the tumor cases are newly disclosed. The rare genetic disease treatment uses a viral vector that has raised safety concerns regarding DNA integration. Advocates are sounding alarms on social media and SMA patient groups are actively seeking more details from doctors about potential treatment risks.

   Why it matters

   The spinal muscular atrophy therapy Zolgensma relies on an adeno-associated viral vector, a common tool in gene therapy that researchers now worry carries unexpected oncogenic risks. While the Food and Drug Administration label previously listed tumor risk as theoretical, these new cases are forcing physicians and families to reevaluate treatment decisions. The inquiry highlights broader safety scrutiny facing adeno-associated virus delivery platforms across the biotechnology sector.

   What is confirmed

   • Novartis confirmed nine reported cases of tumors in patients treated with Zolgensma.
   • Seven of the tumor cases among Zolgensma patients are newly disclosed.
   • The Food and Drug Administration has launched an investigation into the tumour risk tied to the Novartis gene therapy.
   • Zolgensma is a spinal muscular atrophy gene therapy.

   Still unconfirmed

   • Novartis confirmed Zolgensma's viral vector caused tumors in two children via DNA integration.

   What to watch next

   • Findings and regulatory actions from the Food and Drug Administration investigation into Zolgensma
   • Further responses from spinal muscular atrophy advocacy groups regarding treatment guidelines
   Sources used for this update (16)

   1. www.statnews.com — STAT — Reporting from the frontiers of health and medicine
   2. www.frontiersin.org — Frontiers | Flood Susceptibility Modeling in a Subtropical Humid Low-Relief Alluvial Plain Environment: Application of Novel Ensem....
   3. www.cap.org — CAP Review And Forecast: 2025 Financial Update - CAP
   4. BioSpace — Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
   5. Endpoints News — Seven new tumor cases reported among patients on Novartis’ Zolgensma gene therapy
   6. Reuters — FDA probes tumour risk tied to Novartis gene therapy
   7. Fierce Pharma — Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details
   8. SWI swissinfo.ch — Novartis reports cases of tumours in children following treatment with Zolgensma
   9. STAT — New tumor cases show common gene therapy tool can come with risk
   10. Endpoints News — FDA launches investigation of Novartis’ Zolgensma after cancer cases
   11. www.biospace.com — Novartis confirms 9 reported cases of tumors in patients ...
   12. www.genengnews.com — Novartis Confirms Nine Cases of Tumors in Children Treated ...
   confidence 100%